Ahead of ad­comm, FDA rais­es safe­ty ques­tions for As­traZeneca’s re­ver­sal agent for life-threat­en­ing bleeds

The FDA on Thurs­day will con­vene an ad­vi­so­ry com­mit­tee to dis­cuss the safe­ty and ef­fi­ca­cy of As­traZeneca’s An­dexxa, which won ac­cel­er­at­ed ap­proval in 2018 to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER